US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Mentice strengthens cardiology education in Germany through partnership

Mentice has entered into a strategic partnership with the German Society of Cardiology (DGK) and its interventional cardiology working group, AGIK, which focuses on catheter-based treatment of cardiovascular diseases. The purpose of the partnership is to raise the standard of training for cardiologists and improve patient care in Germany by offering advanced training modules based on Mentice’s simulation solutions.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/mentice-strengthens-cardiology-education-in-germany-through-partnership/

BioStock: Mentice updates strategy and goals at Capital Markets Day

On March 21, Mentice arranged a Capital Markets Day in Stockholm, where the management presented the company’s updated financial targets and strategic direction. The event was also attended by two guest lecturers, Dr. Demetrius Lopes and Michael Lee, who discussed the benefits of Mentice’s simulation solutions for healthcare and the medical technology sector.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/mentice-updates-strategy-and-goals-at-capital-markets-day/ This is a press release from BioStock - Connecting Innovation &

Mentice AB (publ) receives an order of USD 540,000 for simulation solutions from Corewell Health, Grand Rapids, Michigan, USA

Sweden-Gothenburg, December 30, 2022 Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Corewell Health, Grand Rapids, Michigan USA, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of USD 540,000. For more information, please contact: Göran Malmberg, CEO, MenticeE-post: goran.malmberg@mentice.com US Mobile. +1 (312) 860 5610Sweden Mobile +46 (0) 703 09 22 22 About Mentice Mentice (STO: MNTC) is the world leader in

Mentice Receives Grant from Sweden’s Innovation Agency to Improve Synthetic Image Generation

Mentice has received a 3 million SEK grant from the Swedish government agency for innovation, Vinnova, to improve realism in Mentice virtual reality software environment with a focus on synthetic image generation. Mentice will be a part of a joint European research project called the TASTI project, financed by Vinnova within the Eureka Xecs cluster.   “The work to be done in the scope of the TASTI project will further increase the realism of our solutions in several ways. It will not only improve our current products but will open doors to new applications, where our synthetic images are

Siemens Healthineers to demonstrate capabilities of Corindus CorPath GRX Robotic System using Mentice VIST ® Simulator

Mentice, a world leader in simulation solutions for image-guided interventional therapies, announced today that Siemens Healthineers China is showcasing the capabilities of the Corindus CorPath GRX Robotic PCI system by using the Mentice VIST ® Virtual Patient simulator. This year’s China International Import Expo (CIIE 2022) will be the first event to showcase the CorPath GRX Robotic System and Mentice VIST ® Virtual Patient integration. The VIST ® Virtual Patient simulator enables Siemens Healthineers to demonstrate the unique capabilities of the CorPath GRX Robotic System effectively

Mentice Launches New Website

Sweden – Gothenburg, October 27, 2022. Mentice, a world leader in virtual and physical simulation solutions for Image-guided Interventional Therapies, is pleased to announce the launch of its new website www.mentice.com.Mentice is proud to present the platform’s innovative design, structure, and content to the clinical and MedTech communities. The new website is designed to inspire and guide visitors in search of customized solutions and services that can support their organization and facilitate procedural and device adoption, knowledge transfer, building relationships, and focusing on

Mentice publishes the company’s interim report for the period July – Sept 2022

CONTINUOUS STRONG DEMAND FROM THE HOSPITAL MARKET · Continued overall growth for the first nine months, mainly driven by Hospital and Strategic Alliances while Medical Device Industry remains on the same level as last year while remaining to be the largest contributor. · Larger order received for Ultrasound solutions during the quarter further articulating the opportunity within the Echocardiography market. · Executive team consisting of 5 standing members, furthermore, a consolidation of VIST software development to Gothenburg and a short-term freeze of hiring and consultants in

Mentice publishes the company’s interim report for the period July – Sept 2022

CONTINUOUS STRONG DEMAND FROM THE HOSPITAL MARKET · Continued overall growth for the first nine months, mainly driven by Hospital and Strategic Alliances while Medical Device Industry remains on the same level as last year while remaining to be the largest contributor. · Larger order received for Ultrasound solutions during the quarter further articulating the opportunity within the Echocardiography market. · Executive team consisting of 5 standing members, furthermore, a consolidation of VIST software development to Gothenburg and a short-term freeze of hiring and consultants in

Mentice and Acandis GmbH announce a 3-year agreement for Mentice Ankyras clinical support software solutions at a value of 8.9mSEK.

Sweden-Gothenburg and Germany-Pforzheim, October 25, 2022 .  Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Acandis, Pforzheim, a leading innovator of minimal invasive devices for the treatment of neurovascular diseases, has signed a 3-year collaboration agreement to further develop the Acandis clinical support platform and supply their customers with Mentice Ankyras clinical support software solutions, for an order value of 8.9mSEK Dr. Schüssler, CEO of Acandis,

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on October 26 at 10:00 CEST

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.To register for the presentation of the interim report for the period July – September 2022, which will be held on October 26 at 10:00 CEST, visit https://investor.mentice.com/ The presentation will be held in English. Participants are advised to register at least a few minutes in advance.

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2023

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company’s Annual General Meeting 2023 has been appointed.At the Annual General Meeting held on 27[th] of April 2022, it was resolved to adopt instructions and rules of procedure for the nomination committee to which the nomination committee shall consist of the chairman of the board of directors and three ordinary members representing the three largest shareholders by 30[th] of September. The

Mentice AB (publ) receives an order of USD 620,000 for simulation solutions and development services

Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that a leading global healthcare technology company, has signed an agreement to acquire Mentice VIST® simulation solutions and development services, for an order of USD 620,000. “Working with leading innovative partners, we value the opportunity to collaborate in this space to achieve the ambition to improve healthcare and ultimately the care for patients”, says Göran Malmberg, CEO and Group president for Mentice, “this project focusing on our Intracardiac

Mentice publishes the company’s interim report for the period April – June 2022

The acquisition of Ankyras is finalized and a large order in the quarter · The order book increased to 108.9 (67.9) MSEK and compared to 87.1 MSEK at the end of 2021. · We acquired all relevant assets relating to Ankyras from Galgo Medical in Spain on the 30th of June. · A significant order of 1.93 MUSD for development and systems from a large medical device company in the US was received. · Higher cost levels during the quarter affecting the result and continued long payment terms with customers affects our cash flow. · We performed a direct issue of shares in the quarter

Mentice AB (STO: MNTC) completes the acquisition of ANKYRAS

Sweden-Gothenburg, 30th June, 2022 .Mentice AB (STO: MNTC)(”Mentice”) Mentice today confirms the acquisition of the Ankyras business from Galgo Medical SL, as previously communicated via the press release on 9th June 2022, now has been completed. The information was submitted for release, through the requestof the contact person below, at 21:20 CEST on 30 June 2022.For more information, please contact:Göran Malmberg, CEOTelefon: +46 70309 22 22E-mail: goran.malmberg@mentice.com About MenticeMentice (STO: MNTC) is the world leader in

Mentice receives an initial order of USD 1.93million for simulation solutions and development services from Medtronic

Sweden-Gothenburg,  June 29, 2022 . Mentice, Gothenburg (STO: MNTC), a world leader in simulation solutions for image-guided interventional therapies, announced today that Medtronic, Dublin (NYSE: MDT), a global healthcare technology leader, has signed an agreement to acquire Mentice VIST® simulation solutions and development services, in an initial order of USD 1.93 million. The initial order includes the development services and 10 simulation solutions for delivery in 2022 raising to an additional intention of 150 simulation solutions over 3 years.

June 9, 2022 Mentice AB acquires all assets related to the software solution Ankyras from the Spanish corporation Galgo Medical S.L.

In accordance with the press release published on 9 June 2022, Mentice AB (publ) (“Mentice” or the “Company”), has entered into an agreement (the “Agreement”) to acquire all assets relating to the software solution Ankyras (“Ankyras”) from Galgo Medical S.L. (“Galgo”) (the “Acquisition”), which was conditional on the receipt of external financing. In accordance with the press release published on 9 June 2022, Mentice has received such external financing through a directed new share issue and thereby fulfilled the condition of the financing in the Agreement.The Acquisition Mentice has, as

Stockholm June 9, 2022 Mentice AB completes a directed new share issue of approximately SEK 60 million which was significantly oversubscribed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Mentice AB (“Mentice” or the “Company”) has, in accordance with the intention announced in the Company’s press release earlier today, carried out a

Stockholm June 9, 2022 Mentice AB explores the conditions for carrying out a directed share issue of approximately SEK 60 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Mentice AB (“Mentice” or the “Company”) hereby announces intention to carry out a directed new issue of shares of approximately SEK 60 million directed to

Mentice AB intends to acquire all assets related to the software solution Ankyras from the Spanish corporation Galgo Medical S.L. June 9, 2022

Mentice AB (publ) (“Mentice” or the “Company”), a leading provider of high-tech solutions for decision support and productivity with the medical field of image guided interventional therapies, announces the intention to acquire all assets of the Ankyras software suite (“Ankyras”) from Galgo Medical S.L. (“Galgo”) for an amount of EUR 1.80 million (approximately SEK 18.78 million[1]) with a possible additional purchase amount of EUR 0.975 million (approximately SEK 10.17 million[1]), and with a total purchase consideration amounting to approximately EUR 2.775 million (about SEK 28.95 million[1]

Communique from annual general meeting in Mentice AB

Press release 2022-04-27An annual general meeting was held in Mentice AB on 27 April 2022. Below follows a summary of the resolutions made at the meeting. Adoption of the income statement and the balance sheet, the consolidated income statement and the consolidated balance sheet and discharge from liability At the annual general meeting the income statement and the balance sheet, the consolidated income statement and the consolidated balance sheet for 2021 were adopted. The meeting resolved to discharge each member of the board of directors alongside with the CEO from liability for

Mentice publishes the company’s interim report for the period January–March 2022

A strong start for the year with continued overall growth· Our strong finish of 2021 is now followed by a first quarter of 2022 with considerable growth for both order intake and net sales. We increased the order book to 91.4 (72.9) MSEK compared to the end of 2021 (87.1) MSEK. · The orderbook now consists of 72% Annual Recurring Revenue based components adding up to 66 MSEK out of the total of 91.4 MSEK. · Net sales for the first quarter of 53.1 (32.3) MSEK, corresponding to an increase of 64.2% compared to the same period last year and the order intake was 54.4 (39.9) MSEK an

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on April 27 at 10:00 CEST

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.To register for the presentation of the interim report for the period January – March 2022, which will be held on April 27 at 10:00 CEST, visit www.mentice.com/financial-reports-presentations. The presentation will be held in English. Participants are advised to register at least a few minutes in advance.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media